SCHEMBL1944225

SCHEMBL1944225

Fc1cccc(Cl)c1CC1CO1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.50
CYP2A13 Q16696 1/20 0.47
GAA P10253 2/20 0.47
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 3/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 2/20 0.41
BACE1 P56817 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
CYP3A4 P08684 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40
ALDH1A1 P00352 2/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28859704 0.80 TAAR1 (0.37) TAAR1CYP2A13KMT2AKDM4EHTT
SCHEMBL8846948 0.73 TSHR (0.47) GAAKMT2AKDM4EMAPTHTT
SCHEMBL3619338 0.72 TAAR1 (0.62) TAAR1
SCHEMBL3619335 0.72 TAAR1 (0.62) TAAR1
SCHEMBL1907932 0.71 TAAR1 (0.35) TAAR1CYP2A13KMT2AHTTNPSR1
SCHEMBL27434539 0.71 ALDH1A1 (0.38) KDM4EMAPTPOLBHPGDCYP3A4
SCHEMBL11790818 0.70 LMNA (0.50) TAAR1GAAKMT2AKDM4EMAPT
SCHEMBL28596017 0.70 TAAR1 (0.63) TAAR1CYP2A13GAAKMT2AKDM4E
SCHEMBL601569 0.70 TAAR1 (0.63) TAAR1CYP2A13GAAKMT2AKDM4E
SCHEMBL30776827 0.70 TAAR1 (0.63) TAAR1CYP2A13GAAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507239-B1 AZACYCLIC SPIRO DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-03-13 EP disclosed
US-8389539-B2 Azacyclic derivatives HOFFMAN-LA ROCHE INC. (US) 2013-03-05 US disclosed
EP-2507239-A1 AZACYCLIC SPIRO DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-10 EP disclosed
WO-2011067166-A1 AZACYCLIC SPIRO DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-09 WO disclosed
US-20110130417-A1 NEW AZACYCLIC DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130417-A1 NEW AZACYCLIC DERIVATIVES AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A1 TAAR1 2139/4885CYP2A13 56/4885GAA 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.